Peptidomimetics in cancer chemotherapy.
A summary of the current status of the application of peptidomimetics in cancer therapeutics as an alternative to peptide drugs is provided. Only compounds that are used in therapy or at least under clinical trials are discussed, using inhibitors of farnesyltransferase, proteasome and matrix metalloproteinases as examples.
Avendaño
C
C
Departamento de Química Orgánica y Farmacéutica, Universidad Complutense, Madrid, Spain. avendano@farm.ucm.es
Menéndez
J C
JC
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D032701:Biomimetics / Q000379:methods*; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D045726:Metalloproteases / Q000037:antagonists & inhibitors / Q000378:metabolism; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D015398:Signal Transduction; D048490:raf Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D010455:Peptides; D061988:Proteasome Inhibitors; D051231:Farnesyltranstransferase; D048490:raf Kinases; D045726:Metalloproteases; D046988:Proteasome Endopeptidase Complex